Book Summary: The Real Anthony Fauci P.19

Ivermectin

(Part2)

• Multiple studies support Dr. McCullough’s findings, indicating an average mortality reduction of 75% based on 18 trials.
• A WHO-sponsored meta-review of 11 studies suggests ivermectin can reduce COVID-19 mortality by up to 83%.
• Seven meta-analyses revealed a large benefit of ivermectin, with a death reduction ranging from 57% to 83%.
• Prophylactic use of ivermectin demonstrated a prevention rate of 86% for adverse outcomes.
• In 29 studies on early treatment, ivermectin showed an average benefit of 66%.
• The ivmmeta.org website compiles validated studies for various COVID-19 treatments.
• A January 2021 study in The Lancet indicated ivermectin significantly reduced symptom intensity and duration, as well as viral load.
• Dr. Paul Marik and the FLCCC developed treatment guidelines for COVID, incorporating ivermectin by November 2020 due to emerging evidence.
• FLCCC protocols were peer-reviewed and published in the Journal of Intensive Care Medicine in December 2020.
• Dr. Pierre Kory testified before multiple panels about ivermectin’s benefits, referencing studies showing nearly perfect prevention of transmission and significant recovery rates among hospitalized patients.
• Dr. Kory presented positive data on ivermectin to the NIH COVID-19 Treatment Guidelines Panel alongside Dr. Andrew Hill’s research.
• Dr. Hill’s meta-analysis of six studies revealed a cumulative 75% reduction in death risk for moderate to severe COVID-19 patients using ivermectin.
• NIH issued a non-recommendation for ivermectin (IVM) on January 14, 2021, claiming insufficient evidence for its use against COVID-19, despite strong safety and efficacy claims.
• The deliberation process was kept secret, with NIH refusing to disclose panel member identities and contesting transparency requests in federal court.
• The CDC eventually revealed the panel’s nine members, three of whom had financial ties to Merck, while Susanna Naggie received a significant grant to study ivermectin after the non-recommendation.
• As the U.S. moves to eliminate IVM use, other countries, such as Japan and India, have embraced it, reporting significant COVID-19 treatment successes.
• Indonesia’s government authorized IVM, resulting in rapid declines in cases and deaths shortly after implementation.
• Studies indicate that countries using IVM widely report lower COVID case and mortality rates, with specific success noted in the African Programme for Onchocerciasis member nations.
• India’s New Delhi state saw a dramatic drop in COVID-19 cases after including IVM in its treatment protocol, effectively mitigating an epidemic crisis.